Tirbanibulin 1% ointment is a topical field therapy approved for actinic keratoses (AKs) of the face and scalp, administered through a concise 5-day regimen with minimal local skin reactions (LSRs).1 Although field therapies are often deferred during warmer months, concerns regarding ultraviolet (UV) exposure and treatment tolerability lack systematic validation in real-world settings
Tirbanibulin 1% real‐world use in 679 actinic keratoses patients during warm season ( SUMM ‐ AK study) / Carugno, A.; Nazzaro, G.; Argnani, L.; Bellinato, F.; Zappia, E.; Masala, M. V.; Dal Bello, G.; Valenti, M.; Addari, G.; Ciccarese, G.; Bruni, M.; Trovato, E.; Paolino, G.; Balestri, R.; D'Arino, A.; Magnoni, C.; Zavattaro, E.; Toni, G.; Giuffrida, R.; Verdelli, A.; Caccavale, S.; Villani, A.; Giacalone, S.; Recalcati, S.; Barruscotti, S.; Bighetti, S.; Bettolini, L.; Fiorillo, G.; Germi, L.; Fazio, S.; Infusino, S. D.; Eibenschutz, L.; Cesari, A.; Dragotto, M.; Zolo, G. B. M.; Savoia, P.; Zalaudek, I.; Sala, E.; Errichetti, E.; Mercuri, S. R.; Esposito, M.; Foti, C.; Atzori, L.; Ardigò, M.; Danese, P.; Ribero, S.; Gisondi, P.; Marzano, A. V.; Zerbinati, N.. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - (2025), pp. N/A-N/A. [10.1111/jdv.70217]
Tirbanibulin 1% real‐world use in 679 actinic keratoses patients during warm season ( SUMM ‐ AK study)
Magnoni, C.;Toni, G.;Villani, A.;Fazio, S.;Zalaudek, I.Membro del Collaboration Group
;Sala, E.;Foti, C.;
2025-01-01
Abstract
Tirbanibulin 1% ointment is a topical field therapy approved for actinic keratoses (AKs) of the face and scalp, administered through a concise 5-day regimen with minimal local skin reactions (LSRs).1 Although field therapies are often deferred during warmer months, concerns regarding ultraviolet (UV) exposure and treatment tolerability lack systematic validation in real-world settingsPubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
